DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the allowance of a composition of matter patent for its lead asset, STM-01, a novel nCPC product. Recently, a composition of matter patent was also issued for STM-21, the company’s lead secretome product derived from nCPC..

达拉斯--（商业新闻短讯）--生物技术公司Secretome Therapeutics今天宣布允许其主要资产STM-01（一种新型nCPC产品）的物质组成专利。最近，该公司从nCPC衍生的主要分泌蛋白产品STM-21也获得了物质组成专利。。

These patents substantially strengthen Secretome’s intellectual property portfolio as the company advances its pipeline forward. Composition of matter patents provide comprehensive protection for the molecular structure of therapeutic products. Secretome Therapeutics is currently the only holder of intellectual property related to nCPC, and the current patent portfolio provides protection through 2035..

这些专利大大加强了Secretome的知识产权组合，因为该公司正在推进其管道。物质专利的组成为治疗产品的分子结构提供了全面的保护。Secretome Therapeutics目前是与nCPC相关的知识产权的唯一持有人，目前的专利组合提供到2035年的保护。。

“With these patents in place, we can confidently move our development candidates forward as we prepare to launch two Phase 1 studies for STM-01 by the end of this year,” said Vinny Jindal, President and CEO of Secretome Therapeutics. “These patents not only protect the molecular integrity of STM-01 and STM-21 but also underscore our potential to develop multiple products derived from nCPC for the treatment of a wide array of diseases driven by chronic inflammation.”.

Secretome Therapeutics总裁兼首席执行官维尼·金达尔（VinnyJindal）表示：“有了这些专利，我们可以自信地推动我们的开发候选人向前发展，因为我们准备在今年年底之前启动STM-01的两项第一阶段研究。”。“这些专利不仅保护了STM-01和STM-21的分子完整性，而且强调了我们开发源自nCPC的多种产品以治疗由慢性炎症驱动的多种疾病的潜力。”。

About STM-01 and STM-21

关于STM-01和STM-21

• STM-01: STM-01 is a novel cellular therapy designed to address severe cardiovascular diseases, particularly dilated cardiomyopathy (DCM) and heart failure with preserved ejection fraction (HFpEF). nCPCs release a unique set of paracrine factors that reduce inflammation, inhibit fibrosis and support tissue repair.

•STM-01:STM-01是一种新型细胞疗法，旨在解决严重的心血管疾病，特别是扩张型心肌病（DCM）和射血分数（HFpEF）保留的心力衰竭。NCPC释放一组独特的旁分泌因子，可减轻炎症，抑制纤维化并支持组织修复。

STM-01 is poised to become a first-in-class treatment, with the company planning to commence first-in-human studies before the end of 2024..

STM-01有望成为一流的治疗方法，该公司计划在2024年底之前开始人体研究。。

• STM-21: This secretome-based therapeutic is comprised of the bioactive molecules secreted by nCPCs, such as cytokines and exosomes, which promote cellular repair and reduce inflammation. STM-21 is in preclinical development for conditions driven by chronic inflammation, including skin wounds and the co-morbidities of diabetes, with additional preclinical data expected in 2025..

•STM-21：这种基于分泌组的治疗剂由NCPC分泌的生物活性分子组成，如细胞因子和外泌体，可促进细胞修复并减少炎症。STM-21正在针对由慢性炎症驱动的疾病进行临床前开发，包括皮肤伤口和糖尿病合并症，预计2025年将有更多临床前数据。。

About Secretome Therapeutics, Inc.

关于Secretome Therapeutics，Inc。

Secretome Therapeutics, based in Dallas, Texas, is developing innovative therapies from neonatal cardiac progenitor cells to treat cardiovascular diseases and other underserved diseases driven by inflammation.

位于德克萨斯州达拉斯的Secretome Therapeutics正在开发新生儿心脏祖细胞的创新疗法，以治疗心血管疾病和其他由炎症驱动的服务不足的疾病。